keyword
MENU ▼
Read by QxMD icon Read
search

Gynecologic oncology group

keyword
https://www.readbyqxmd.com/read/28196674/cost-effectiveness-analysis-of-dose-dense-versus-standard-intravenous-chemotherapy-for-ovarian-cancer-an-economic-analysis-of-results-from-the-gynecologic-oncology-group-protocol-262-randomized-controlled-trial
#1
Brandon-Luke L Seagle, Shohreh Shahabi
OBJECTIVES: To determine the cost-effectiveness of dose-dense versus standard intravenous adjuvant chemotherapy for ovarian cancer using results from the no-bevacizumab cohort of the Gynecologic Oncology Group protocol 262 (GOG-262) randomized controlled trial, which reported a smaller absolute progression-free survival (PFS) benefit than the prior Japanese trial. METHODS: A three-state Markov decision model from a healthcare system perspective with a 21day cycle length and 28month time-horizon was used to calculate incremental cost-effectiveness ratio (ICER) values per progression-free life-year saved (PFLYS) using results from GOG-262...
February 10, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28190981/the-role-of-intraperitoneal-carboplatin-as-consalidation-chemotherapy-in-women-with-ovarian-carcinoma-report-of-our-experience-and-systematic-review
#2
Azamsadat Mousavi, Mojgan Karimi-Zarchi, Nadere Behtash, Mitra Modares-Gilani, Mahnaz Mokhtari-Gorgani, Nili Mehrdad, Mitra Rouhi, Pouria Yazdian Anari
BACKGROUND: Epithelial ovarian cancer is the leading cause of death from gynecology malignancy. The aim of this study was to assess the role of intraperitoneal chemotherapy with carboplatin, as a consolidative treatment, in reducing relapse and increasing survival of patients in advanced epithelial ovarian cancers, as well as evaluation of its toxicity. METHODS: This clinical trial was conducted on 30 patients with epithelial ovarian cancer in stages II-IV in Gynecology oncology department in Valiasr University Hospital, Tehran during 2005-2010...
December 2016: International Journal of Biomedical Science: IJBS
https://www.readbyqxmd.com/read/28190649/factors-associated-with-deciding-between-risk-reducing-salpingo-oophorectomy-and-ovarian-cancer-screening-among-high-risk-women-enrolled-in-gog-0199-an-nrg-oncology-gynecologic-oncology-group-study
#3
Phuong L Mai, Marion Piedmonte, Paul K Han, Richard P Moser, Joan L Walker, Gustavo Rodriguez, John Boggess, Thomas J Rutherford, Oliver Zivanovic, David E Cohn, J Tate Thigpen, Robert M Wenham, Michael L Friedlander, Chad A Hamilton, Jamie Bakkum-Gamez, Alexander B Olawaiye, Martee L Hensley, Mark H Greene, Helen Q Huang, Lari Wenzel
OBJECTIVES: Women at increased genetic risk of ovarian cancer (OC) are recommended to have risk-reducing salpingo-oophorectomy (RRSO) after completion of reproductive planning. Effective screening has not been established, and novel screening modalities are being evaluated. METHODS: Participants chose either RRSO or a novel OC screening regimen (OCS) as their risk management option, and provided demographic and other data on BRCA mutation status, cancer worry, perceived intervention risks/benefits, perceived cancer risk, and quality-of-life at enrollment...
February 10, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28187091/a-new-scoring-tool-to-assess-overall-survival-in-patients-with-intracerebral-metastases-from-gynecological-cancers
#4
Dirk Rades, Stefan Janssen, Amira Bajrovic, Theo Veninga, Dorothea Fischer, Steven E Schild
OBJECTIVE: This study aimed to facilitate individualized treatment strategies for intracerebral metastases from gynecological cancers by creating a specific overall survival (OS) score. METHODS/MATERIALS: Fifty-six patients irradiated for cerebral metastases from gynecological cancers were included. Eleven factors were retrospectively analyzed for OS: age, Eastern Cooperative Oncology Group (ECOG) performance score, cancer type, histology, histologic grading, initial stage, number of lesions, extracerebral metastases, time between cancer diagnosis and brain metastases treatment, recursive partitioning analysis class, and type of treatment...
March 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28173966/nutrition-interventions-in-patients-with-gynecological-cancers-requiring-surgery
#5
Andreas Obermair, Marko Simunovic, Liz Isenring, Monika Janda
OBJECTIVE: Including developing countries, between 20 and 88% of gynecological oncology patients may present with at least mild malnutrition at diagnosis. Significant morbidity and mortality is attributed to malnutrition. Here we reviewed randomized clinical trials of nutritional interventions used to achieve early return to oral diet, enhance recovery from surgery and reduce adverse events in gynecological cancer patients undergoing surgery. METHODS: Ebscohost (CINAHL+Medline+PsycINFO), Cochrane, Embase, PubMed and Scopus databases were searched for articles published from 2000 onwards...
February 4, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28156639/determining-priority-symptoms-of-women-with-recurrent-ovarian-cancers-a-gynecologic-oncology-group-study
#6
Lari B Wenzel, Sandra Ward, Susan M Sereika, Robert P Edwards, Michael Spring, Catherine M Bender, Richard T Penson, Teresa Hagan
: 101 Background: The purpose of this study is to recommend a core set of priority symptoms to be assessed in research and clinical settings for women with recurrent ovarian cancers. METHODS: We used baseline data of 497 women with recurrent ovarian, fallopian, or primary peritoneal cancer participating in a symptom management randomized clinical trial (GOG-0259) to identify a core index of patient-reported priority symptoms. We used the Symptom Representation Questionnaire to assess priority rankings of 28 symptoms based on four criteria: (1) symptom prevalence, (2) patient-reported symptom severity, (3) percentage of women identifying each symptom as one of top three symptoms "I would like to get better control over", and (4) the association between symptom severity and functional wellbeing as measured by the Functional Assessment of Cancer Therapy - Ovarian...
October 9, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28156596/impact-of-support-group-participation-in-women-with-gynecologic-cancer
#7
Adam Pyrzak, Fengjiao Hu, Ramses F Sadek, Donna Wheatley, Bunja Jane Rungruang, Sharad A Ghamande
: 252 Background: Unlike breast cancer support group literature, there is no data in women with gynecologic cancer who have different perspectives about their disease and therapy. We have a well-established, grass root level support group unique to women with gynecologic cancers that meets monthly. Our goal was to investigate perceived benefits of support group participation. METHODS: We developed an original questionnaire to evaluate the CSRA Gynecologic Oncology Support Group (CGOSG) participant's perceived effects of attending the group on their side effects and disease status which was distributed to patients attending CGOSG meetings...
October 9, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28152913/moving-towards-hospital-and-radiation-oncology-emr-integration-results-of-an-institutional-survey
#8
Murat Surucu, Barbara Kaczmarz, Teresita McCoo, John Roeske, William Small
: 152 Background: We are working to electronically integrate our radiation oncology EMR and our hospital EMR to improve communication and facilitate patient care. To guide integration, we surveyed providers and support staff at our academic cancer center to identify the important encounters/documents and how well these are currently communicated. METHODS: We sent an email survey to 182 MDs, nurses, and administrative staff at our cancer center. Respondents identified their role in the patient care team, and rated how important several radiation oncology-specific encounters/documents from "not important at all" to "extremely important" and rated the accessibility of these encounters/documents from "not at all accessible" to "exceptionally accessible...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28143870/early-detection-of-ovarian-cancer-using-the-risk-of-ovarian-cancer-algorithm-with-frequent-ca125-testing-in-women-at-increased-familial-risk-combined-results-from-two-screening-trials
#9
Steven J Skates, Mark H Greene, Saundra S Buys, Phuong L Mai, Powel H Brown, Marion Piedmonte, Gustavo C Rodriguez, John O Schorge, Mark Sherman, Mary B Daly, Thomas J Rutherford, Wendy R Brewster, David M O'Malley, Edward E Partridge, John Boggess, Charles W Drescher, Claudine Isaacs, Andrew Berchuck, Susan M Domchek, Susan A Davidson, Robert P Edwards, Steven A Elg, Katie Wakeley, Kelly-Anne Phillips, Deborah K Armstrong, Ira R Horowitz, Carol J Fabian, Joan Walker, Patrick M Sluss, William R Welch, Lori Minasian, Nora Horick, Carol H Kasten, Susan Nayfield, David S Alberts, Dianne M Finkelstein, Karen Lu
PURPOSE: Women at familial/genetic ovarian cancer risk often undergo screening despite unproven efficacy. Research suggests each woman has her own CA125 baseline; significant increases above this level may identify cancers earlier than standard 6-12 monthly CA125>35U/mL. EXPERIMENTAL DESIGN: Data from prospective Cancer Genetics Network and Gynecologic Oncology Group trials, which screened 3,692 women (13,080 woman-screening years) with a strong breast/ovarian cancer family history or BRCA1/2 mutations, were combined to assess a novel screening strategy...
January 31, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28114237/robotic-and-advanced-laparoscopic-surgical-training-in-european-gynecological-oncology-trainees
#10
Carmen Gan, Michaela Bossart, Jurgen Piek, Michael Halaska, Dimitrios Haidopoulos, Ignacio Zapardiel, Jacek P Grabowski, Vesna Kesic, Rainer Kimmig, David Cibula, Eric Lambaudie, Rene Verheijen, Ranjit Manchanda
INTRODUCTION: Advanced minimal access surgical training is an important component of training in gynecological oncology (GO). Europe-wide data on this topic are lacking. We present data on availability and trainee experience of advanced laparoscopic surgical (ALS) and robotic surgical (RS) training in GO across Europe. METHOD: A prospective web-based anonymized survey of European GO trainees was sent to the European Network of Young Gynaecological Oncologists members/trainees...
February 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28104497/robot-assisted-surgery-in-gynecologic-cancers
#11
REVIEW
V Zanagnolo, A Garbi, M T Achilarre, L Minig
Robotic-assisted surgery is a technological advancement that facilitates the application of minimally invasive techniques for complex operations in gynecological oncology. The objective of this article is to review the literature regarding the role of robotic-assisted surgery to treat women with gynecologic cancers. The majority of publications on robotic surgery are still retrospective or descriptive in nature, however, the data for managing patients with a robotic assisted approach shows comparable, and at times an improved outcomes compared to both laparoscopy (2D) and laparotomy approaches...
January 16, 2017: Journal of Minimally Invasive Gynecology
https://www.readbyqxmd.com/read/28094040/a-phase-2-study-of-alisertib-mln8237-in-recurrent-or-persistent-uterine-leiomyosarcoma-an-nrg-oncology-gynecologic-oncology-group-study-0231d
#12
David M Hyman, Michael W Sill, Heather A Lankes, Richard Piekarz, Mark S Shahin, Mildred R Ridgway, Floor Backes, Meaghen E Tenney, Cara A Mathews, James S Hoffman, Carol Aghajanian, Martee L Hensley
OBJECTIVE: This two-stage Phase II study assessed the activity of single agent alisertib in patients with recurrent/persistent uterine leiomyosarcoma (uLMS). METHODS: Eligibility criteria included histologically-confirmed, recurrent or persistent uLMS, age≥18, 1-2 prior cytotoxic regimens, and RECIST version 1.1 measurable disease. The primary objective of the study was to evaluate the efficacy of alisertib through the frequency of patients with objective tumor responses and the frequency who survived event-free for at least 6months (EFS6)...
January 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28089376/chemotherapy-completion-in-elderly-women-with-ovarian-primary-peritoneal-or-fallopian-tube-cancer-an-nrg-oncology-gynecologic-oncology-group-study
#13
Vivian E von Gruenigen, Helen Q Huang, Jan H Beumer, Heather A Lankes, William Tew, Thomas Herzog, Arti Hurria, Robert S Mannel, Tina Rizack, Lisa M Landrum, Peter G Rose, Ritu Salani, William H Bradley, Thomas J Rutherford, Robert V Higgins, Angeles Alvarez Secord, Gini Fleming
PURPOSE: A simple measure to predict chemotherapy tolerance in elderly patients would be useful. We prospectively tested the association of baseline Instrumental Activities of Daily Living (IADL) score with ability to complete 4 cycles of first line chemotherapy without dose reductions or >7days delay in elderly ovarian cancer patients. PATIENTS AND METHODS: Patients' age ≥70 along with their physicians chose between two regimens: CP (Carboplatin AUC 5, Paclitaxel 135mg/m(2)) or C (Carboplatin AUC 5), both given every 3weeks either after primary surgery or as neoadjuvant chemotherapy (NACT) with IADL and quality of life assessments performed at baseline, pre-cycle 3, and post-cycle 4...
January 12, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28079776/enhanced-recovery-program-and-length-of-stay-after-laparotomy-on-a-gynecologic-oncology-service-a-randomized-controlled-trial
#14
Elizabeth L Dickson, Erica Stockwell, Melissa A Geller, Rachel Isaksson Vogel, Sally A Mullany, Rahel Ghebre, Boris J N Witherhoff, Levi S Downs, Linda F Carson, Deanna Teoh, Michelle Glasgow, Matt Gerber, Colleen Rivard, Britt K Erickson, Jacob Hutchins, Peter A Argenta
OBJECTIVE: To estimate whether a rapid recovery program would reduce length of stay among patients undergoing laparotomy on a gynecologic oncology service. METHODS: We conducted a prospective, randomized, controlled trial comparing an enhanced recovery after surgery protocol with routine postoperative care among women undergoing laparotomy on the gynecologic oncology service. Protocol elements included: preoperative counseling, regional anesthesia, intraoperative fluid restriction, and early postoperative ambulation and feeding...
February 2017: Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28068938/acupuncture-combined-with-methylcobalamin-for-the-treatment-of-chemotherapy-induced-peripheral-neuropathy-in-patients-with-multiple-myeloma
#15
Xiaoyan Han, Lijuan Wang, Hongfei Shi, Gaofeng Zheng, Jingsong He, Wenjun Wu, Jimin Shi, Guoqing Wei, Weiyan Zheng, Jie Sun, He Huang, Zhen Cai
BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) seriously affects the quality of life of patients with multiple myeloma (MM) as well as the response rate to chemotherapy. Acupuncture has a potential role in the treatment of CIPN, but at present there have been no randomized clinical research studies to analyze the effectiveness of acupuncture for the treatment of CIPN, particularly in MM patients. METHODS: The MM patients (104 individuals) who met the inclusion criteria were randomly assigned into a solely methylcobalamin therapy group (500 μg intramuscular methylcobalamin injections every other day for 20 days; ten injections) followed by 2 months of 500 μg oral methylcobalamin administration, three times per day) and an acupuncture combined with methylcobalamin (Met + Acu) group (methylcobalamin used the same way as above accompanied by three cycles of acupuncture)...
January 9, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28067948/preoperative-assessment-of-lymph-node-metastasis-in-endometrial-cancer-a-korean-gynecologic-oncology-group-study
#16
Sokbom Kang, Joo-Hyun Nam, Duk-Soo Bae, Jae-Weon Kim, Moon-Hong Kim, Xiaojun Chen, Jae-Hong No, Jong-Min Lee, Jae-Hoon Kim, Hidemich Watari, Seok Mo Kim, Sung Hoon Kim, Seok Ju Seong, Ki Tae Kim, Seung Cheol Kim, Jong-Hyeok Kim, Myung-Cheol Lim, Jung-Yun Lee, Sang-Young Ryu, Bingyi Yang, Byoung-Gie Kim
BACKGROUND: Previously proposed criteria for preoperatively identifying endometrial cancer patients at low risk for lymph node metastasis remain to be verified. For this purpose, a prospective, multicenter observational study was performed. METHODS: Eligible patients with histologically confirmed endometrial cancer underwent magnetic resonance imaging (MRI) and serum cancer antigen 125 (CA 125) testing before surgery. The following criteria were used to identify low-risk patients: 1) endometrioid-type cancer, 2) no evidence of deep myometrial invasion on MRI, 3) no enlarged lymph nodes on MRI, 4) no suspicious metastasis out of the uterine corpus, and 5) serum CA 125 levels less than 35 U/mL...
January 1, 2017: Cancer
https://www.readbyqxmd.com/read/28060140/gynecologic-oncologist-views-influencing-referral-to-outpatient-specialty-palliative-care
#17
Casey M Hay, Carolyn Lefkowits, Megan Crowley-Matoka, Marie A Bakitas, Leslie H Clark, Linda R Duska, Renata R Urban, Lee-May Chen, Stephanie L Creasy, Yael Schenker
OBJECTIVE: Early specialty palliative care is underused for patients with advanced gynecologic malignancies. We sought to understand how gynecologic oncologists' views influence outpatient specialty palliative care referral to help inform strategies for improvement. METHODS/MATERIALS: We conducted a qualitative interview study at 6 National Cancer Institute-designated cancer centers with well-established outpatient palliative care services. Between September 2015 and March 2016, 34 gynecologic oncologists participated in semistructured telephone interviews focused on attitudes, experiences, and preferences related to outpatient specialty palliative care...
March 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28040721/vulvar-cancer-version-1-2017-nccn-clinical-practice-guidelines-in-oncology
#18
Wui-Jin Koh, Benjamin E Greer, Nadeem R Abu-Rustum, Susana M Campos, Kathleen R Cho, Hye Sook Chon, Christina Chu, David Cohn, Marta Ann Crispens, Don S Dizon, Oliver Dorigo, Patricia J Eifel, Christine M Fisher, Peter Frederick, David K Gaffney, Ernest Han, Susan Higgins, Warner K Huh, John R Lurain, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, Amanda Nickles Fader, Steven W Remmenga, R Kevin Reynolds, Todd Tillmanns, Stefanie Ueda, Fidel A Valea, Emily Wyse, Catheryn M Yashar, Nicole McMillian, Jillian Scavone
Vulvar cancer is a rare gynecologic malignancy. Ninety percent of vulvar cancers are predominantly squamous cell carcinomas (SCCs), which can arise through human papilloma virus (HPV)-dependent and HPV-independent pathways. The NCCN Vulvar Cancer panel is an interdisciplinary group of representatives from NCCN Member Institutions consisting of specialists in gynecological oncology, medical oncology, radiation oncology, and pathology. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Vulvar Cancer provide an evidence- and consensus-based approach for the management of patients with vulvar SCC...
January 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28029447/a-phase-ii-evaluation-of-ixabepilone-in-the-treatment-of-recurrent-persistent-carcinosarcoma-of-the-uterus-an-nrg-oncology-gynecologic-oncology-group-study
#19
Carolyn K McCourt, Wei Deng, Don S Dizon, Heather A Lankes, Michael J Birrer, Michele M Lomme, Matthew A Powell, James E Kendrick, Joel N Saltzman, David Warshal, Meaghan E Tenney, David M Kushner, Carol Aghajanian
BACKGROUND: The primary objectives were to determine the objective response rate (ORR) and safety profile of ixabepilone in women with recurrent or persistent uterine carcinosarcoma (UCS). Secondary objectives included progression-free survival (PFS) and overall survival (OS). Exploratory translational objectives included characterization of class III beta tubulin expression and its association with response, PFS, and OS. METHODS: Patients had measurable disease; up to two prior chemotherapeutic regimens were allowed, but must have included a taxane...
January 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28028994/an-open-label-multicenter-phase-i-trial-of-a-cremophor-free-polymeric-micelle-formulation-of-paclitaxel-combined-with-carboplatin-as-a-first-line-treatment-for-advanced-ovarian-cancer-a-korean-gynecologic-oncology-group-study-kgog-3016
#20
Shin Wha Lee, Yong Man Kim, Young Tae Kim, Soon Beom Kang
OBJECTIVE: This phase I study aimed to determine the maximum tolerated dose (MTD) of Genexol-PM, when combined with carboplatin, as a first-line treatment in patients with advanced ovarian cancer. METHODS: This open-label, multicenter, phase I, dose-escalation study included 18 patients (median age: 59.0 years, range: 40-75 years) diagnosed with advanced epithelial ovarian cancer. All patients had measurable residual disease after debulking surgery. Patients were assigned to groups (n=6 each group) that received different doses of Genexol-PM (220, 260, and 300 mg/m², once every 3 weeks) and 5 area under the curve (AUC) carboplatin...
December 19, 2016: Journal of Gynecologic Oncology
keyword
keyword
59468
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"